Axsome Therapeutics (NASDAQ:AXSM) released its quarterly earnings results on Thursday. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.15), Fidelity Earnings reports.

Axsome Therapeutics stock traded up $2.19 during midday trading on Friday, hitting $25.46. The stock had a trading volume of 738,300 shares, compared to its average volume of 1,457,869. The stock has a market cap of $889.38 million, a P/E ratio of -22.14 and a beta of 2.61. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.72. Axsome Therapeutics has a 12 month low of $1.94 and a 12 month high of $30.50. The business has a fifty day moving average price of $22.15 and a 200 day moving average price of $23.50.

In other news, CFO Nick Pizzie bought 2,180 shares of the business’s stock in a transaction on Thursday, September 26th. The stock was purchased at an average cost of $24.80 per share, for a total transaction of $54,064.00. Following the completion of the transaction, the chief financial officer now directly owns 40,440 shares of the company’s stock, valued at approximately $1,002,912. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 27.50% of the company’s stock.

AXSM has been the topic of several recent analyst reports. Zacks Investment Research upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 7th. Guggenheim began coverage on Axsome Therapeutics in a report on Wednesday, October 16th. They issued a “buy” rating and a $48.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Axsome Therapeutics in a report on Thursday, October 17th. BidaskClub raised Axsome Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, October 26th. Finally, ValuEngine raised Axsome Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 1st. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $35.13.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.

Recommended Story: Oversold

Earnings History for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.